The exercise period for warrants of series TO7 in Prolight Diagnostics begins today
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.
Today, on October 7, 2024, the exercise period begins for warrants of series TO7 in Prolight Diagnostics AB (publ) (“Prolight” or the “Company”). The exercise period runs until October 18, 2024. Each warrant of series TO7 entitles the holder to subscribe for one (1) new share in the Company at a price of SEK 0.12 per share. If all warrants of series TO7 are exercised, the Company will receive approximately SEK 13.1 million before issue costs. For the warrants not to expire without value, it is required that the holder exercises the warrants for subscription of shares no later than October 18, 2024, or alternatively sells the warrants no later than October 15, 2024.
Full terms and conditions for the warrants are available at the Company's website, www.prolightdx.com.
Summarized terms for the warrants of series TO7:
Exercise period: October 7, 2024 – October 18, 2024.
Exercise price: SEK 0.12 per share.
Issue size: 108,756,747 warrants of series TO7 entitling to subscription of 108,756,747 shares. If all the warrants are exercised the Company will receive approximately SEK 13.1 million before issuing costs.
Last day for trading with warrants of series TO7: October 15, 2024.
Note that the warrants that are not exercised at latest on October 18, 2024, or sold at the latest on October 15, 2024, will expire without value. For the warrants not to lose their value, the holder must actively exercise the warrants for subscription of new shares or sell the warrants. Please observe that certain nominees might close their application earlier than October 18, 2024.
Shares, share capital, and dilution
If all warrants of series TO7 are exercised the total number of shares in the Company will increase by 108,756,747, from 597,287,105 shares to 706,043,852 shares, and the share capital will increase with SEK 10,875,674.70, from SEK 59,728,710.50 to SEK 70,604,385.20. This corresponds to a maximum dilution of approximately 15.4 percent of the total number of shares and 15.4 percent of the total number of votes in the Company. The dilution effect has been calculated as the number of additional shares and votes, respectively, in relation to the number of existing and additional shares and votes, respectively.
How the warrants are exercised:
Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Direct-registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscription will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
The application form including instructions for payment will be available at the Company’s website, www.prolightdx.com.
Advisors
Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the exercise of the warrants of series TO7.